Full text is available at the source.
Abstract
CAR T cell therapy faces challenges in solid tumors due to T cell dysfunction and exhaustion.
- The solid tumor microenvironment may contribute to reduced effectiveness of CAR T cells through decreased cytotoxicity and proliferation.
- Inhibitory receptors are upregulated in CAR T cells, resembling the behavior of tumor-infiltrating lymphocytes.
- Innovative strategies, such as locoregional delivery and enhancing CAR T cells with interleukin-18, are being explored to improve treatment outcomes.
- Management of adverse events associated with CAR T cell therapy presents emerging toxicity issues that require attention.
- Current and future strategies are being discussed to address the obstacles faced by CAR T cell therapy in solid tumors.
Simplified